Baidu
map

JAHA:急性冠脉综合征后HIV感染与长期心血管风险之间的关系

2020-08-26 MedSci原创 MedSci原创

尽管PLHIV和HIV未感染者之间发生重大不良心脏和脑血管事件的总体风险在统计学上无显著差异,但PLHIV发生复发性ACS的几率更高。

目前尚不清楚HIV感染是否会影响急性冠脉综合征(ACS)患者的长期预后。近日,血管疾病领域权威杂志JAHA上发表了一篇研究文章,该研究的目的是比较HIV感染者(PLHIV)与HIV未感染者之间首次ACS后主要心脏和脑血管不良事件的发生率,并确定心血管预后的决定因素。

研究人员从法国23个冠心病重症监护病房中招募了连续就诊首次ACS的PLHIV和相匹配的HIV未感染者。根据患者年龄、性别和ACS类型对患者进行匹配。该研究的主要终点是在36个月的随访中发生的主要不良心脏和脑血管事件(心脏死亡、复发性ACS、复发冠状动脉血运重建和卒中)。

该研究总共纳入了103名PLHIV和195名HIV未感染者(平均年龄为49岁[SD为9岁];男性占94.0%)。在平均36.6个月(SD为6.1个月)的随访之后,PLHIV和HIV未感染者之间发生主要不良心脏和脑血管事件的风险无统计学差异(分别为17.8%和15.1%,P=0.22;多变量风险比[HR]为1.60;95%CI为0.67-3.82[P=0.29])。在PLHIV中ACS的复发率更高(多变量HR为6.31;95%CI为1.32-30.31[P=0.02])。分层多变量Cox模型发现HIV感染是ACS复发的唯一独立预测因素。PLHIV戒烟的可能性较小(47% vs. 75%;P=0.01),总胆固醇下降程度较小(–22.3 vs. –35.0 mg/dL;P=0.04)。

尽管PLHIV和HIV未感染者之间发生重大不良心脏和脑血管事件的总体风险在统计学上无显著差异,但PLHIV发生复发性ACS的几率更高。

原始出处:

Franck Boccara.et al.HIV Infection and Long‐Term Residual Cardiovascular Risk After Acute Coronary Syndrome.J AM HEART ASSOC.2020.https://www.ahajournals.org/doi/full/10.1161/JAHA.119.017578

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (13)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2082542, encodeId=6355208254279, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Sat Mar 06 15:12:58 CST 2021, time=2021-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882340, encodeId=ad738823407a, content=好好学习!, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200818/141c99cdc65c44bf83b75c8508f8f782/2288a4580d98499baacf5be18653e6a0.jpg, createdBy=b9945378046, createdName=ms6000000572095183, createdTime=Thu Sep 03 07:56:36 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268313, encodeId=401512683135d, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Aug 28 11:12:58 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431926, encodeId=0f981431926da, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Aug 28 11:12:58 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814321, encodeId=63e981432197, content=标记一下回头来看, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ce05381686, createdName=ms4000002082197205, createdTime=Thu Aug 27 22:01:48 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813984, encodeId=0ccf813984b8, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 10:55:38 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813937, encodeId=d7b581393e50, content=相关资讯请继续分享,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:12:31 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813878, encodeId=98928138e8ac, content=很好很详细,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:01:22 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813632, encodeId=337b8136323f, content=嗯, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 07:04:33 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813594, encodeId=4f5581359438, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fb682417917, createdName=1238d654m87暂无昵称, createdTime=Wed Aug 26 22:34:49 CST 2020, time=2020-08-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2082542, encodeId=6355208254279, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Sat Mar 06 15:12:58 CST 2021, time=2021-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882340, encodeId=ad738823407a, content=好好学习!, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200818/141c99cdc65c44bf83b75c8508f8f782/2288a4580d98499baacf5be18653e6a0.jpg, createdBy=b9945378046, createdName=ms6000000572095183, createdTime=Thu Sep 03 07:56:36 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268313, encodeId=401512683135d, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Aug 28 11:12:58 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431926, encodeId=0f981431926da, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Aug 28 11:12:58 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814321, encodeId=63e981432197, content=标记一下回头来看, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ce05381686, createdName=ms4000002082197205, createdTime=Thu Aug 27 22:01:48 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813984, encodeId=0ccf813984b8, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 10:55:38 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813937, encodeId=d7b581393e50, content=相关资讯请继续分享,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:12:31 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813878, encodeId=98928138e8ac, content=很好很详细,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:01:22 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813632, encodeId=337b8136323f, content=嗯, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 07:04:33 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813594, encodeId=4f5581359438, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fb682417917, createdName=1238d654m87暂无昵称, createdTime=Wed Aug 26 22:34:49 CST 2020, time=2020-08-26, status=1, ipAttribution=)]
    2020-09-03 ms6000000572095183

    好好学习!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2082542, encodeId=6355208254279, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Sat Mar 06 15:12:58 CST 2021, time=2021-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882340, encodeId=ad738823407a, content=好好学习!, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200818/141c99cdc65c44bf83b75c8508f8f782/2288a4580d98499baacf5be18653e6a0.jpg, createdBy=b9945378046, createdName=ms6000000572095183, createdTime=Thu Sep 03 07:56:36 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268313, encodeId=401512683135d, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Aug 28 11:12:58 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431926, encodeId=0f981431926da, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Aug 28 11:12:58 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814321, encodeId=63e981432197, content=标记一下回头来看, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ce05381686, createdName=ms4000002082197205, createdTime=Thu Aug 27 22:01:48 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813984, encodeId=0ccf813984b8, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 10:55:38 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813937, encodeId=d7b581393e50, content=相关资讯请继续分享,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:12:31 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813878, encodeId=98928138e8ac, content=很好很详细,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:01:22 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813632, encodeId=337b8136323f, content=嗯, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 07:04:33 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813594, encodeId=4f5581359438, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fb682417917, createdName=1238d654m87暂无昵称, createdTime=Wed Aug 26 22:34:49 CST 2020, time=2020-08-26, status=1, ipAttribution=)]
    2020-08-28 zhaohui6731
  4. [GetPortalCommentsPageByObjectIdResponse(id=2082542, encodeId=6355208254279, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Sat Mar 06 15:12:58 CST 2021, time=2021-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882340, encodeId=ad738823407a, content=好好学习!, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200818/141c99cdc65c44bf83b75c8508f8f782/2288a4580d98499baacf5be18653e6a0.jpg, createdBy=b9945378046, createdName=ms6000000572095183, createdTime=Thu Sep 03 07:56:36 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268313, encodeId=401512683135d, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Aug 28 11:12:58 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431926, encodeId=0f981431926da, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Aug 28 11:12:58 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814321, encodeId=63e981432197, content=标记一下回头来看, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ce05381686, createdName=ms4000002082197205, createdTime=Thu Aug 27 22:01:48 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813984, encodeId=0ccf813984b8, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 10:55:38 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813937, encodeId=d7b581393e50, content=相关资讯请继续分享,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:12:31 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813878, encodeId=98928138e8ac, content=很好很详细,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:01:22 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813632, encodeId=337b8136323f, content=嗯, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 07:04:33 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813594, encodeId=4f5581359438, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fb682417917, createdName=1238d654m87暂无昵称, createdTime=Wed Aug 26 22:34:49 CST 2020, time=2020-08-26, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2082542, encodeId=6355208254279, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Sat Mar 06 15:12:58 CST 2021, time=2021-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882340, encodeId=ad738823407a, content=好好学习!, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200818/141c99cdc65c44bf83b75c8508f8f782/2288a4580d98499baacf5be18653e6a0.jpg, createdBy=b9945378046, createdName=ms6000000572095183, createdTime=Thu Sep 03 07:56:36 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268313, encodeId=401512683135d, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Aug 28 11:12:58 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431926, encodeId=0f981431926da, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Aug 28 11:12:58 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814321, encodeId=63e981432197, content=标记一下回头来看, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ce05381686, createdName=ms4000002082197205, createdTime=Thu Aug 27 22:01:48 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813984, encodeId=0ccf813984b8, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 10:55:38 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813937, encodeId=d7b581393e50, content=相关资讯请继续分享,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:12:31 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813878, encodeId=98928138e8ac, content=很好很详细,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:01:22 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813632, encodeId=337b8136323f, content=嗯, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 07:04:33 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813594, encodeId=4f5581359438, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fb682417917, createdName=1238d654m87暂无昵称, createdTime=Wed Aug 26 22:34:49 CST 2020, time=2020-08-26, status=1, ipAttribution=)]
    2020-08-27 ms4000002082197205

    标记一下回头来看

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2082542, encodeId=6355208254279, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Sat Mar 06 15:12:58 CST 2021, time=2021-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882340, encodeId=ad738823407a, content=好好学习!, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200818/141c99cdc65c44bf83b75c8508f8f782/2288a4580d98499baacf5be18653e6a0.jpg, createdBy=b9945378046, createdName=ms6000000572095183, createdTime=Thu Sep 03 07:56:36 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268313, encodeId=401512683135d, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Aug 28 11:12:58 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431926, encodeId=0f981431926da, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Aug 28 11:12:58 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814321, encodeId=63e981432197, content=标记一下回头来看, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ce05381686, createdName=ms4000002082197205, createdTime=Thu Aug 27 22:01:48 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813984, encodeId=0ccf813984b8, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 10:55:38 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813937, encodeId=d7b581393e50, content=相关资讯请继续分享,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:12:31 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813878, encodeId=98928138e8ac, content=很好很详细,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:01:22 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813632, encodeId=337b8136323f, content=嗯, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 07:04:33 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813594, encodeId=4f5581359438, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fb682417917, createdName=1238d654m87暂无昵称, createdTime=Wed Aug 26 22:34:49 CST 2020, time=2020-08-26, status=1, ipAttribution=)]
    2020-08-27 14818eb4m67暂无昵称

    学习了

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2082542, encodeId=6355208254279, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Sat Mar 06 15:12:58 CST 2021, time=2021-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882340, encodeId=ad738823407a, content=好好学习!, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200818/141c99cdc65c44bf83b75c8508f8f782/2288a4580d98499baacf5be18653e6a0.jpg, createdBy=b9945378046, createdName=ms6000000572095183, createdTime=Thu Sep 03 07:56:36 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268313, encodeId=401512683135d, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Aug 28 11:12:58 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431926, encodeId=0f981431926da, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Aug 28 11:12:58 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814321, encodeId=63e981432197, content=标记一下回头来看, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ce05381686, createdName=ms4000002082197205, createdTime=Thu Aug 27 22:01:48 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813984, encodeId=0ccf813984b8, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 10:55:38 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813937, encodeId=d7b581393e50, content=相关资讯请继续分享,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:12:31 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813878, encodeId=98928138e8ac, content=很好很详细,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:01:22 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813632, encodeId=337b8136323f, content=嗯, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 07:04:33 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813594, encodeId=4f5581359438, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fb682417917, createdName=1238d654m87暂无昵称, createdTime=Wed Aug 26 22:34:49 CST 2020, time=2020-08-26, status=1, ipAttribution=)]
    2020-08-27 ms7000000689223974

    相关资讯请继续分享,谢谢

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2082542, encodeId=6355208254279, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Sat Mar 06 15:12:58 CST 2021, time=2021-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882340, encodeId=ad738823407a, content=好好学习!, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200818/141c99cdc65c44bf83b75c8508f8f782/2288a4580d98499baacf5be18653e6a0.jpg, createdBy=b9945378046, createdName=ms6000000572095183, createdTime=Thu Sep 03 07:56:36 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268313, encodeId=401512683135d, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Aug 28 11:12:58 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431926, encodeId=0f981431926da, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Aug 28 11:12:58 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814321, encodeId=63e981432197, content=标记一下回头来看, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ce05381686, createdName=ms4000002082197205, createdTime=Thu Aug 27 22:01:48 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813984, encodeId=0ccf813984b8, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 10:55:38 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813937, encodeId=d7b581393e50, content=相关资讯请继续分享,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:12:31 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813878, encodeId=98928138e8ac, content=很好很详细,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:01:22 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813632, encodeId=337b8136323f, content=嗯, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 07:04:33 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813594, encodeId=4f5581359438, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fb682417917, createdName=1238d654m87暂无昵称, createdTime=Wed Aug 26 22:34:49 CST 2020, time=2020-08-26, status=1, ipAttribution=)]
    2020-08-27 ms7000000689223974

    很好很详细,谢谢分享

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2082542, encodeId=6355208254279, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Sat Mar 06 15:12:58 CST 2021, time=2021-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882340, encodeId=ad738823407a, content=好好学习!, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200818/141c99cdc65c44bf83b75c8508f8f782/2288a4580d98499baacf5be18653e6a0.jpg, createdBy=b9945378046, createdName=ms6000000572095183, createdTime=Thu Sep 03 07:56:36 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268313, encodeId=401512683135d, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Aug 28 11:12:58 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431926, encodeId=0f981431926da, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Aug 28 11:12:58 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814321, encodeId=63e981432197, content=标记一下回头来看, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ce05381686, createdName=ms4000002082197205, createdTime=Thu Aug 27 22:01:48 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813984, encodeId=0ccf813984b8, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 10:55:38 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813937, encodeId=d7b581393e50, content=相关资讯请继续分享,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:12:31 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813878, encodeId=98928138e8ac, content=很好很详细,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:01:22 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813632, encodeId=337b8136323f, content=嗯, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 07:04:33 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813594, encodeId=4f5581359438, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fb682417917, createdName=1238d654m87暂无昵称, createdTime=Wed Aug 26 22:34:49 CST 2020, time=2020-08-26, status=1, ipAttribution=)]
    2020-08-27 14818eb4m67暂无昵称

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2082542, encodeId=6355208254279, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Sat Mar 06 15:12:58 CST 2021, time=2021-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882340, encodeId=ad738823407a, content=好好学习!, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200818/141c99cdc65c44bf83b75c8508f8f782/2288a4580d98499baacf5be18653e6a0.jpg, createdBy=b9945378046, createdName=ms6000000572095183, createdTime=Thu Sep 03 07:56:36 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268313, encodeId=401512683135d, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Aug 28 11:12:58 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431926, encodeId=0f981431926da, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Aug 28 11:12:58 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814321, encodeId=63e981432197, content=标记一下回头来看, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ce05381686, createdName=ms4000002082197205, createdTime=Thu Aug 27 22:01:48 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813984, encodeId=0ccf813984b8, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 10:55:38 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813937, encodeId=d7b581393e50, content=相关资讯请继续分享,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:12:31 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813878, encodeId=98928138e8ac, content=很好很详细,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:01:22 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813632, encodeId=337b8136323f, content=嗯, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 07:04:33 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813594, encodeId=4f5581359438, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fb682417917, createdName=1238d654m87暂无昵称, createdTime=Wed Aug 26 22:34:49 CST 2020, time=2020-08-26, status=1, ipAttribution=)]
    2020-08-26 1238d654m87暂无昵称

    0

相关资讯

Circulation:三种口服P2Y12抑制剂治疗急性冠脉综合征的疗效对比

口服P2Y12抑制剂的新随机对照试验已经在急性冠状动脉综合征中展开。本研究旨在通过随机对照试验的荟萃分析,评估比较普拉格雷、替格瑞洛和氯吡格雷在急性冠脉综合征中的疗效和安全性。

NAT COMMUN:优于临床医生,机器学习助力急性冠脉综合征预测 

目前,迅速识别急性冠脉综合征仍然是临床实践中的一个重要挑战。12导联心电图(ECG)在患者初始评估时很容易获得,但基于当前规则的解释方法缺乏足够的准确性。

类似于急性冠脉综合征及中风,你会想起该病吗?

嗜酸性肉芽肿性多血管炎,也称为Churg-Strauss综合征(churg-strauss syndrome,CSS),以哮喘、嗜酸性粒细胞增多及血管炎为临床表现的、累及多器官的罕见疾病。

Circulation:心血管疾病患者采用阿司匹林抗凝的最适持续时间

AUGUSTUS试验显示,房颤、近期发生过急性冠脉综合征和经皮冠状动脉介入治疗的患者采用阿哌沙班治疗的出血事件少于采用维生素K拮抗剂(VKA),安慰剂处理的少于服用阿司匹林的。但安慰剂组的缺血事件量明

Int J Cardiol:肾功能不全患者被忽视!中国急性冠脉综合征临床路径项目新分析

在中国急性冠脉综合征患者中,肾功能不全的患者较少接受指南推荐的治疗策略,其临床预后也较差。

Circulation:峰回路转!有效降低双重抗血小板疗法出血风险的新策略

阿司匹林和P2Y12抑制剂的双重抗血小板疗法已被证实可降低PCI或急性冠脉综合征后的MACE风险,但同时会增加出血风险。本研究旨在评估停用阿司匹林而采用P2Y12抑制剂单一疗法的安全性。

Baidu
map
Baidu
map
Baidu
map